Viskoper J R, Laszt A, Faraggi D
Department of Medicine B, Barzilai Medical Center, Ashkelon, Israel.
Am J Hypertens. 1991 Feb;4(2 Pt 2):161S-162S. doi: 10.1093/ajh/4.2.161s.
The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years, with hypertension. After withdrawal of previous antihypertensive treatment and a four-week placebo period, patients were randomized into a double-blind active-treatment period of eight weeks to receive either placebo or 1.25 to 2.5 mg isradipine twice daily. Twenty-four-hour ambulatory blood pressure was measured by Accutracker (Suntech, Oxford, England) after the placebo period and at the end of the active-treatment period. In the isradipine group n = 13), both systolic and diastolic blood pressure and number of blood pressure spikes decreased significantly (P less than .0001), whereas there was a significant increase of these variables in the placebo control group (n = 13). The results of this study indicate that, in these subjects, blood pressure control was achieved throughout the 24-h period by monotherapy with isradipine.
对26名年龄在40至64岁之间的男性高血压患者评估了伊拉地平的降压效果。在停用先前的抗高血压治疗并经过四周的安慰剂期后，患者被随机分为为期八周的双盲活性治疗期，每日两次接受安慰剂或1.25至2.5毫克伊拉地平治疗。在安慰剂期结束时以及活性治疗期结束时，使用Accutracker（英国牛津Suntech公司）测量24小时动态血压。在伊拉地平组（n = 13）中，收缩压和舒张压以及血压峰值次数均显著降低（P <.0001），而在安慰剂对照组（n = 13）中这些变量则显著增加。本研究结果表明，在这些受试者中，通过伊拉地平单一疗法可在24小时内实现血压控制。
